H3B-6527 / Eisai  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
H3B-6527 / Eisai
NCT03424577: A Study to Evaluate the Food-Effect of H3B-6527

Completed
1
17
US
H3B-6527
Eisai Inc., H3 Biomedicine Inc.
Healthy Participants
01/18
01/18
H3B-6527-G000-101, NCT02834780: Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

Hourglass Apr 2018 - Sep 2018 : Recommended P2 dose in P1/2 trial in HCC
Checkmark From trial for HCC
Jan 2018 - Jan 2018: From trial for HCC
Completed
1
128
Europe, Canada, US, RoW
H3B-6527
H3 Biomedicine Inc., Eisai Inc.
Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Hepatic Cancer, Hepatic Carcinoma
02/22
02/22

Download Options